<scp>LncRNA MIR22HG</scp> is downregulated in adenomyosis and upregulates <scp>miR</scp>‐2861 through demethylation to inhibit endometrial cell proliferation

Yu, Ke; Cui, Shuna; Xue, Tongmin

doi:10.1111/jog.14665

Cited by 3 publications

(2 citation statements)

References 24 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both MIR22HG and miRNA-2861 were significantly downregulated in AM patient tissues. Cell proliferation assays revealed that MIR22HG may upregulate miRNA-2861 through demethylation, which in turn downregulates STAT3 and MMP2 and inhibits endometrial cell proliferation, suggesting that MIR22HG and miRNA-2861 overexpression may be potential therapeutic target genes for AM ( Yu et al, 2021 ). Taken together, these data suggest that EXOs can regulate cell proliferation and apoptosis through the proteins and miRNAs they transport, thus participating in the development of AM.…”

Section: Relevance Of Exos In Am Pathogenesismentioning

confidence: 99%

Exosomes: potential diagnostic markers and drug carriers for adenomyosis

Cheng,

Wei,

Zhou

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Adenomyosis is a common benign gynecological disorder and an important factor leading to infertility in fertile women. Adenomyosis can cause deep lesions and is persistent and refractory in nature due to its tumor-like biological characteristics, such as the ability to implant, adhere, and invade. The pathogenesis of adenomyosis is currently unclear. Therefore, new therapeutic approaches are urgently required. Exosomes are nanoscale vesicles secreted by cells that carry proteins, genetic materials and other biologically active components. Exosomes play an important role in maintaining tissue homeostasis and regulating immune responses and metabolism. A growing body of work has shown that exosomes and their contents are key to the development and progression of adenomyosis. This review discusses the current research progress, future prospects and challenges in this emerging therapeutic tool by providing an overview of the changes in the adenomyosis uterine microenvironment and the biogenesis and functions of exosomes, with particular emphasis on the role of exosomes and their contents in the regulation of cell migration, proliferation, fibrosis formation, neovascularization, and inflammatory responses in adenomyosis.

show abstract

Section: Relevance Of Exos In Am Pathogenesismentioning

confidence: 99%

Exosomes: potential diagnostic markers and drug carriers for adenomyosis

Cheng,

Wei,

Zhou

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…It has been demonstrated that several microRNAs are dysregulated in endometrium from adenomyosis patients, raising hopes of developing a treatment by normalizing expression of these molecules [ 74 ]. According to subsequent studies, let-7a, miR-145-5p, miR-17, and miR-2861 have all been found to be differentially expressed in adenomyosis and may constitute targets for development of novel therapies against the disease [ 75 , 76 , 77 , 78 ]. Nevertheless, there is still a huge gap to bridge between in vitro studies and development of a drug for clinical application, with the first ever small RNA-based therapeutic (patisiran) only obtaining FDA approval as recently as 2018.…”

Section: Medical Treatment Of Adenomyosismentioning

confidence: 99%

Conservative Management of Uterine Adenomyosis: Medical vs. Surgical Approach

Stratopoulou

Donnez

Dolmans

2021

JCM

View full text Add to dashboard Cite

Uterine adenomyosis is a commonly encountered estrogen-dependent disease in reproductive-age women, causing heavy menstrual bleeding, intense pelvic pain, and infertility. Although adenomyosis was previously considered a disease of multiparous women, it is becoming increasingly evident that it also affects younger nulliparous women and may compromise their fertility potential. It is clear that hysterectomy, the standard approach to definitively manage the disease, is not an option for patients wishing to preserve their fertility, so there is an urgent need to develop novel conservative strategies. We searched the current literature for available methods for conservative management of adenomyosis, including both pharmacological and surgical approaches. There is no existing drug that can cure adenomyosis at present, but some off-label treatment options may be used to tackle disease symptoms and improve fertility outcomes. Adenomyosis in patients wishing to conceive can be ‘treated’ by conservative surgery, though these procedures require highly experienced surgeons and pose a considerable risk of uterine rupture during subsequent pregnancies. While currently available options for conservative management of adenomyosis do have some capacity for alleviating symptoms and enhancing patient fertility perspectives, more effective new options are needed, with gonadotropin-releasing hormone antagonists showing encouraging results in preliminary studies.

show abstract

Overview of crosstalk between stromal and epithelial cells in the pathogenesis of adenomyosis and shared features with deep endometriotic nodules

Zipponi,

Cacciottola,

Dolmans

2024

Human Reproduction

View full text Add to dashboard Cite

Since the first description of adenomyosis more than 150 years ago, multiple hypotheses have attempted to explain its pathogenesis. Indeed, research over recent years has greatly enhanced our knowledge of the underlying causes. This has opened up avenues for the development of strategies for both disease prevention and treatment of its main symptoms, such as pelvic pain, heavy menstrual bleeding, and infertility. However, the current means are still largely ineffective, so it is vital that we shed light on the pathways involved. Dysregulated mechanisms and aberrant protein expression have been identified as contributing factors in interactions between endometrial epithelial and stromal cells, ultimately leading to the growth of adenomyotic lesions. These include collective cell migration, epithelial-to-mesenchymal transition, hormonal influence, and signaling from non-coding RNAs and extracellular vesicles. We provide a concise summary of the latest insights into the crosstalk between glands and stroma in ectopic adenomyotic lesion formation. While there is an abundance of literature on similarities between adenomyosis and deep endometriosis, there are insufficient data on the cytochemical, molecular, and pathogenetic mechanisms of these two disorders. However, various shared features, including alterations of cell adhesion molecules, abnormal hormone regulation, and the presence of cancer-driving mutations and epigenetic modifications, have been identified. Nevertheless, the pathogenic mechanisms that contribute to the cause and development of these enigmatic diseases have not been fully elucidated yet.

show abstract

LncRNA MIR22HG is downregulated in adenomyosis and upregulates miR‐2861 through demethylation to inhibit endometrial cell proliferation

Cited by 3 publications

References 24 publications

Exosomes: potential diagnostic markers and drug carriers for adenomyosis

Exosomes: potential diagnostic markers and drug carriers for adenomyosis

Conservative Management of Uterine Adenomyosis: Medical vs. Surgical Approach

Overview of crosstalk between stromal and epithelial cells in the pathogenesis of adenomyosis and shared features with deep endometriotic nodules

Contact Info

Product

Resources

About